EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

OC18 | LONG-TERM EFFECTIVENESS, SAFETY AND TOLERABILITY OF ATOGEPANT IN THE PREVENTION OF MIGRAINE: A MULTICENTRIC, PROSPECTIVE OBSERVATIONAL, REAL WORLD STUDY (THE 48-WEEK STAR STUDY)

Confinia Cephalalgica · 03.11.2026 · 36 (s1)

DOI: 10.4081/cc.2026.15956 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Confinia Cephalalgica, online erschienen am 03.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To investigate the long-term effectiveness, safety and tolerability of atogepant for migraine prevention after 48 weeks of treatment.

Methods

At baseline (T0), weeks 9–12 (T3), 21–24 (T6) and 45-48 weeks (T12), monthly migraine days (MMDs), and main patients’ reported outcomes were assessed. The co-primary outcomes were changes in MMDs and the percentage of MMDs ≥50% responders (50%RR) at T3, T6, and T12 compared to baseline. We also reported the proportion of patients achieving migraine freedom according to the International Headache Society proposal.

Results

Three hundred and seventy (370) patients from 17 Italian centers were enrolled (female 311, 84.1%, age 47.7 SD 0.7). Of these, 57 patients (15.4%) dropped out of treatment within the first 12 weeks; 85 (23.0%) within 24 weeks; and 118 (31.9%) within 48 weeks. Nineteen participants (16,1%) dropped out because of adverse events, 43 (36,4%) for inefficacy, 14 (11,9%) for both adverse events and inefficacy, and 42 (35,6%) for other reasons.In patients continuing therapy for 48 weeks, MMDs decreased from 16.5 (SD 0.5) to 7.8 (SD 0.5; p

Zitieren

APA

(2026). OC18 | LONG-TERM EFFECTIVENESS, SAFETY AND TOLERABILITY OF ATOGEPANT IN THE PREVENTION OF MIGRAINE: A MULTICENTRIC, PROSPECTIVE OBSERVATIONAL, REAL WORLD STUDY (THE 48-WEEK STAR STUDY). Confinia Cephalalgica, 36(s1). https://doi.org/10.4081/cc.2026.15956

Vancouver

OC18 | LONG-TERM EFFECTIVENESS, SAFETY AND TOLERABILITY OF ATOGEPANT IN THE PREVENTION OF MIGRAINE: A MULTICENTRIC, PROSPECTIVE OBSERVATIONAL, REAL WORLD STUDY (THE 48-WEEK STAR STUDY). Confinia Cephalalgica. 2026;36(s1). doi:10.4081/cc.2026.15956

BibTeX
@article{euvimed2026,
  title = {OC18 | LONG-TERM EFFECTIVENESS, SAFETY AND TOLERABILITY OF ATOGEPANT IN THE PREVENTION OF MIGRAINE: A MULTICENTRIC, PROSPECTIVE OBSERVATIONAL, REAL WORLD STUDY (THE 48-WEEK STAR STUDY)},
  journal = {Confinia Cephalalgica},
  year = {2026},
  volume = {36},
  number = {s1},
  doi = {10.4081/cc.2026.15956}
}
Kostenlos starten →